Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Inclusion Criteria

• •Phase I: Histologically confirmed relapsed or refractory non-Hodgkin lymphoma or Hodgkin lymphoma (WHO criteria), with no accepted curative options.
• •Phase II: Relapsed or refractory T-cell lymphoma, including patients with central nervous system (CNS) involvement or lymphomatous meningitis are allowed on study.
• •Relapsed or refractory disease following frontline chemotherapy. No upper limit for the number of prior therapies. Patients may have relapsed after prior autologous or allogeneic stem cell transplant.
• •Evaluable Disease in the Phase I, and measurable disease for the Phase II.
• •Age \> or = 18 years.
• •Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2.
• •Patients must have adequate organ and marrow function.
• •Negative urine or serum pregnancy test for females of childbearing potential.
• •All females of childbearing potential must use an effective barrier method of contraception during the treatment period and for at least 1 month thereafter. Male subjects should use a barrier method of contraception during the treatment period and for at least 3 months thereafter.
• •Ability to understand and the willingness to sign a written informed consent document.